Carlo Croce, the embattled and litigious cancer researcher at The Ohio State University, may be on the market for a new attorney.
Croce, who unsuccessfully sued the New York Times for libel after the newspaper reported on misconduct allegations against him, has been waging a second legal front against his institution. The grounds: Croce wants Ohio State to restore him to his position as chair of the Department of Cancer Biology and Genetics — a demand OSU has so far rejected.
Court documents suggest that the case has proceeded to depositions. But we’ve learned that Croce’s attorneys in the academic matter have dropped him as a client. In a motion approved earlier this month, the lawyers, from the Columbus firm James E. Arnold & Associates, petitioned to be removed from the case.
A scientist for the U.S. government has lost a 2017 paper on spawning in catfish for problems with the data.
The paper, “Effective dose of salmon GnRHa for induction of ovulation in channel catfish,” was written by Nagaraj G. Chatakondi and appeared in the North American Journal of Aquaculture. Chatakondi is a geneticist with the Stoneville, Miss., office of the Agricultural Research Service, a division of the U.S. Department of Agriculture.
A group of ophthalmology researchers in China got caught trying to pull the wool over the eyes of readers by falsely claiming to have used a therapy that doesn’t exist.
As its title would indicate, the article, “Anti-angiogenic effect of Interleukin-26 in oxygen-induced retinopathy mice via inhibiting NFATc1-VEGF pathway,” by a team from Jinhua Municipal Central Hospital in Zhejiang, purported to show that IL-26 could prevent the growth of new blood vessels in mice with damaged retinas.
As we’ve noted before, “the wheels of scientific publishing turn slowly … but they do (sometimes) turn.”
More than six years after the first retraction for Erin Potts-Kant, who was part of a group at Duke whose work would unravel amid misconduct allegations and lead to a $112.5 million settlement earlier this year with the U.S. government — and two years after a journal says it first became aware of the issues — a retraction by the group has appeared in Pediatric Research, a Springer Nature title.
Here’s the retraction notice for “Intra-amniotic LPS amplifies hyperoxia-induced airway hyperreactivity in neonatal rats”:
Following weeks of scrutiny, the daughter of a high-profile official in South Korea has had a paper she wrote as a high school student retracted, in part because the journal determined she had made no intellectual contributions to the study.
Cho Kuk, who was officially appointed yesterday (September 9) as the top justice official in South Korea, is embroiled in a controversy over undeserved academic advantages his daughter, Cho Min, obtained.
According to a story by Reuters about the larger controversy last week:
Earlier this year, Justin Pickett, a criminologist at the University of Albany at the State University of New York, asked journals to look into potentially problematic data in five papers — including one on which he had been a co-author.
As we reported in July, Pickett’s request came after he’d received an anonymous email pointing out issues with the data — concerns ranging from “Anomalies in standard errors, coefficients, and p-values” to “Unlikely survey design and data structure.”
At the time, one of the five articles had already received a correction for a “coding error” that changed the results. Pickett requested that the journal retract the paper entirely, but was rebuffed.
Now, two other journals have taken action on the articles on the list.
Is it possible for just one researcher to perform a clinical trial of more than 200 participants?
According to the editorial board of the European Journal of Obstetrics & Gynecology and Reproductive Biology, an Elsevier title, the answer would seem to be no. The journal has decided to retract a 2016 paper in which the author claimed to have conducted such a large trial on their own.
Here’s the notice for “Calcium versus oral contraceptive pills containing drospirenone for the treatment of mild to moderate premenstrual syndrome: A double blind randomized placebo controlled trial:”
A chemical engineer in China who claims his supporting data were wiped out in a flood has notched his ninth retraction, seven from a single journal, for suspicious images and related issues.
The work of Dong Ge Tong, of Chengdu University of Technology, had come under scrutiny in PubPeer, and several of his articles received expressions of concern before ultimately falling to retraction.
Last week, the Journal of Materials Chemistry A pulled seven papers on which Tong was an author. Here’s the notice for one of those articles, “Hollow amorphous NaFePO4 nanospheres as a high-capacity and high-rate cathode for sodium-ion batteries,” first published in 2015:
The Journal of Biological Chemistry has retracted three papers by a group from the University of California, Los Angeles, citing problems with the figures.
Two of the papers, published in 2002, 2004 and 2009, have the same last author, Mark H. Doolittle, who is the first author of the most recent article. Doolittle, who appears to be a highly talented woodworker, has left UCLA and did not respond to a request for comment.
The retraction notice for the 2002 paper, “Maturation of lipoprotein lipase in the endoplasmic reticulum: Concurrent formation of functional dimers and inactive aggregates,” states: